Ibrutinib-A double-edge sword in cancer and autoimmune disorders

Area of Science:

• Pharmacology and Immunology
• Oncology
• Autoimmune Diseases

Background:

• Targeted therapies, including small molecule inhibitors of tyrosine kinases (TKIs), are emerging as crucial treatments for cancer and autoimmune disorders.
• Tyrosine kinases (TKs) are key targets, with Bruton's tyrosine kinase (Btk) playing a significant role in B-cell receptor signaling.
• Ibrutinib is a TKI targeting Btk and also exhibits immunomodulatory effects by inhibiting IL-2 inducible tyrosine kinase (Itk) in T lymphocytes.

Purpose of the Study:

• To review the inhibitory and immunomodulatory effects of ibrutinib.
• To explore ibrutinib's role in B-cell malignancies, autoimmune diseases, and infections.
• To examine the communication between Ror1 receptor tyrosine kinase and BCR, and ibrutinib's impact on this crosstalk.

Main Methods:

• Review of existing literature on ibrutinib's mechanism of action.
• Analysis of studies investigating ibrutinib's effects on B-cell receptor signaling and T-cell subsets.
• Examination of research on ibrutinib's therapeutic applications in various diseases.

Main Results:

• Ibrutinib covalently binds to and inhibits Btk, impacting B-cell proliferation, differentiation, and survival.
• Ibrutinib modulates the immune system by suppressing T-helper 2 cells and shifting the Th1/Th2 balance towards Th1 cells.
• Ibrutinib demonstrates dual activity, showing potential anti-tumor and immunomodulatory effects.

Conclusions:

• Ibrutinib possesses significant inhibitory and immunomodulatory properties with potential applications in B-cell malignancies, autoimmune diseases, and infections.
• The dual action of ibrutinib warrants further investigation for its therapeutic utility.
• Understanding ibrutinib's interaction with pathways like Ror1-BCR crosstalk is crucial for optimizing its clinical use.